Skip to main content
Key Specialties
Cardiology Diabetology Endocrinology Gastroenterology Geriatrics and Gerontology Gynecology and Obstetrics Hematology Infectious Disease Internal Medicine Nephrology Neurology Oncology Pediatrics Respiratory Medicine Rheumatology Surgery
Congress Coverage
2024 ASCO Annual Meeting 2024 ACC Congress 2023 ESMO Congress 2023 EASD Congress 2023 ERS Congress 2023 ESC Congress
Clinical Collections
Advances in Alzheimer’s

2024 ASCO Annual Meeting

Keep up to date with all the top stories and latest evidence with our hub page, including official congress videos and expert takeaways.
ADVANCED SEARCH
Log in
Top
PharmacoEconomics
Published in: PharmacoEconomics 11/2010

01-11-2010 | Review Article

Economic Implications of Sleep Disorders

Authors: Dr Tracy L. Skaer, David A. Sclar

Published in: PharmacoEconomics | Issue 11/2010

Login to get access

Abstract

Sleep disorders such as insomnia, obstructive sleep apnoea (OSA), excessive daytime sleepiness (EDS) and fatigue, sleep deprivation and restless legs syndrome (RLS) are increasingly seen in clinical practice. Sleep is considered vital for preserving daytime cognitive function and physiological well-being. Sleep insufficiency may have deleterious effects on work-life balance, overall health and safety. The consequential economic burden at both the individual and societal levels is significant. Moreover, sleep disorders are commonly associated with other major medical problems such as chronic pain, cardiovascular disease, mental illness, dementias, gastrointestinal disorders and diabetes mellitus. Thus, in order to properly care for patients presenting with sleep-related morbidity, and to reduce the consequential economic burden, accurate screening efforts and efficacious/cost-effective treatments need to be developed and employed.
Literature
1.
American Academy of Sleep Medicine. International classification of sleep disorders, revised: diagnostic and coding manual. Chicago (IL): American Academy of Sleep Medicine, 2001 [online]. Available from URL: http://​www.​esst.​org/​adds/​ICSD.​pdf [Accessed 2010 Jul 29]
2.
Hossain JL, Shapiro CM. The prevalence, cost implications, and management of sleep disorders: an overview. Sleep Breath 2002; 6 (2): 85–102PubMedCrossRef
3.
4.
Dinges DF, Pack F, Williams K, et al. Cumulative sleepiness, mood disturbance, and psychomotor vigilance performance decrements during a week of sleep restricted to 4–5 hours per night. Sleep 1997; 20: 267–77PubMed
5.
Spiegel K, Leproult R, Van Cauter E. Impact of sleep debt on metabolic and endocrine function. Lancet 1999; 354 (9188): 1435–9PubMedCrossRef
6.
Spiegel K, Leproult R, L’hermite-Balériaux M, et al. Leptin levels are dependent on sleep duration: relationships with sympathovagal balance, carbohydrate regulation, cortisol, and thyrotropin. J Clin Endocrinol Metab 2004; 89 (11): 5762–71PubMedCrossRef
7.
Spiegal K, Tasali E, Penev P, et al. Brief communication: sleep curtailment in healthy young men is associated with decreased leptin levels, elevated ghrelin levels, and increased hunger and appetite. Ann Intern Med 2004; 141 (11): 846–50
8.
Tochikubo O, Ikeda A, Miyajima E, et al. Effects of insufficient sleep on blood pressure monitored by a new multibiomedical recorder. Hypertension 1996; 27: 1318–24PubMedCrossRef
9.
Kato M, Phillips BG, Sigurdsson G, et al. Effects of sleep deprivation on neural circulatory control. Hypertension 2000; 35: 1173–5PubMedCrossRef
10.
Meier-Ewert HK, Ridker PM, Rifai N, et al. Effect of sleep loss on C-reactive protein, an inflammatory marker of cardiovascular risk. J Am Coll Cardiol 2004; 43 (4): 678–83PubMedCrossRef
11.
Kripke DF, Garfinkel L, Wingard DL, et al. Mortality associated with sleep duration and insomnia. Arch Gen Psychiatry 2002; 59 (2): 131–6PubMedCrossRef
12.
13.
Foley DJ, Monjan A, Simonsick EM, et al. Incidence and remission of insomnia among elderly adults: an epidemiologic study of 6800 persons over three years. Sleep 1999; 22 Suppl. 2: S366–72
14.
Morin CM, LeBlanc M, Daley M, et al. Epidemiology of insomnia: prevalence, self-help treatments, consultations, and determinants of help-seeking behaviors. Sleep Med 2006; 7: 123–30PubMedCrossRef
15.
Ohayon MM. Epidemiology of insomnia: what we know and what we still need to learn. Sleep Med Rev 2002; 6 (2): 97–111PubMedCrossRef
16.
Doghramaji K. The epidemiology and diagnosis of insomnia. Am J Manag Care 2006; 12 (8 Suppl.): S214–20
17.
Goldberg LD. Managing insomnia in an evolving marketplace. Am J Manag Care 2006; 12 (8 Suppl.): S212–3
18.
19.
McCrae CS, Lichstein KL. Secondary insomnia: diagnostic challenges and intervention opportunities. Sleep Med Rev 2001; 5: 47–61PubMedCrossRef
20.
Sateia MJ, Doghramji K, Hauri PJ, et al. Evaluation of chronic insomnia: an American Academy of Sleep Medicine review. Sleep 2000; 23 (2): 243–309PubMed
21.
Skaer TL, Robison LM, Sclar DA, et al. Psychiatric comorbidity and pharmacological treatment patterns among patients presenting with insomnia: an assessment of office-based encounters in the USA in 1995 and 1996. Clin Drug Investig 1999; 18 (2): 161–7CrossRef
22.
Skaer TL, Sclar DA, Robison LM. Complaint of insomnia in the United States 1995–1998: prevalence, psychiatric comorbidity, and pharmacologic treatment patterns. Prim Care Psych 2001; 7: 145–51CrossRef
23.
McCall WV. A psychiatric perspective on insomnia. J Clin Psychiatry 2001; 62 Suppl. 10: 27–32
24.
Ancoli-Isreal S. The impact and prevalence of chronic insomnia and other sleep disturbances associated with chronic illness. Am J Manag Care 2006; 12 (8 Suppl.): S221–9
25.
Hatoum HT, Kong SX, Kania CM, et al. Insomnia, healthrelated quality of life and healthcare resource consumption: a study of managed-care organisation enrollees. Pharmacoeconomics 1998; 14 (6): 629–37PubMedCrossRef
26.
Hillman DR, Murphy AS, Pezzullo L. The economic cost of sleep disorders. Sleep 2006; 29 (3): 299–305PubMed
27.
Daley M, Morin CM, LeBlanc M, et al. Insomnia and its relationship to health-care utilization, work absenteeism, productivity, and accidents. Sleep Med 2009; 10: 427–38PubMedCrossRef
28.
Simon GE, VonKorff M. Prevalence, burden, and treatment of insomnia in primary care. AmJ Psychiatry 1997; 154 (10): 1417–23
29.
Silvertsen B, Overland S, Pallesen S, et al. Insomnia and long sleep duration are risk factors for later work disability. The Hordaland Health Study. J Sleep Res 2009; 18 (1): 122–8
30.
Leger D, Guilleminault C, Bader G, et al. Medical and socioprofessional impact of insomnia. Sleep 2002; 25: 625–9PubMed
31.
Walsh JK, Engelhardt CL. The direct economic costs of insomniain theUnited States for 1995. Sleep 1999; 22 Suppl. 2: S386–93
32.
Leger D, Levy E, Paillard M. The direct costs of insomnia in France. Sleep 1999; 22 Suppl. 2: S394–401
33.
Chilcott LA, Shapiro CM. The socioeconomic impact of insomnia: an overview. Pharmacoeconomics 1996; 10 Suppl.1: 1–14PubMedCrossRef
34.
Stoller MK. Economic effects of insomnia. Clin Ther 1994; 16: 873–97PubMed
35.
Ozminkowski RJ, Wang S, Walsh JK. The direct and indirect costs of untreated insomnia in adults in the United States. Sleep 2007; 30: 263–73PubMed
36.
Gottlieb DJ, Whitney CW, Bonekat WH, et al. Relation of sleepiness to respiratory disturbance index: the Sleep Heart Health Study. Am J Respir Crit Care Med 1999; 159: 502–7PubMed
37.
Weaver TE, Chasens ER. Continuous positive airway pressure treatment for sleep apnea in older adults. Sleep Med Rev 2007; 11: 99–111PubMedCrossRef
38.
39.
Nieto FJ, Young TB, Lind BK, et al. Association of sleepdisordered breathing, sleep apnea, and hypertension in a large community-based study. Sleep Heart Health Study [published erratumappears in JAMA 2002; 288 (16): 1985]. JAMA 2000; 283 (14): 1829–36
40.
Peppard PE, Young T, Palta M, et al. Prospective study of the association between sleep-disordered breathing and hypertension. N Engl J Med 2000; 342: 1378–84PubMedCrossRef
41.
Lavie Pk, Here P, Hoffstein V. Obstructive sleep apnea syndrome as a risk factor for hypertension: population study. BMJ 2000; 320: 479–82PubMedCrossRef
42.
Young T, Peppard PE, Gottlieb DJ. Epidemiology of obstructive sleep apnea: a population health perspective. Am J Respir Crit Care Med 2002; 165: 1217–39PubMedCrossRef
43.
Banno K, Walld R, Kryger MH. Increasing obesity trends in patients with sleep-disordered breathing referred to a sleep disorders center. J Clin Sleep Med 2005; 1 (4): 364–6PubMed
44.
Bray GA, Bellanger T. Epidemiology, trends, and morbidities of obesity and the metabolic syndrome. Endocrine 2006; 29: 109–17PubMedCrossRef
45.
Katzmarzyk PT, Mason C. Prevalence of class I, II, and III obesity in Canada. CMAJ 2006; 174: 156–7PubMedCrossRef
46.
Geiss LS, Pan L, Cadwell B, et al. Changes in incidence of diabetes in US adults, 1997–2003. Am J Prev Med 2006; 30: 371–7PubMedCrossRef
47.
48.
Otake K, Delaive K, Walld R, et al. Cardiovascular medication use in patients with undiagnosed obstructive sleep apnoea. Thorax 2002; 57: 417–22PubMedCrossRef
49.
Tarasiuk A, Greenberg-Dotan S, Simon-Tuval T, et al. The effect of obstructive sleep apnea on morbidity and health care utilization of middle-aged and older adults. J Am Geriatr Soc 2008; 56: 247–54PubMedCrossRef
50.
Katzmarzyk PT, Janssen I. The economic costs associated with physical inactivity and obesity in Canada: an update. Can J Appl Physiol 2004; 29: 90–115PubMedCrossRef
51.
Wolf AM, Colditz GA. Current estimates of the economic cost of obesity in the United States. Obes Res 1998; 6: 97–106PubMedCrossRef
52.
Detournay B, Fagnani F, Phillippo M, et al. Obesity morbidity and health care costs in France: an analysis of the 1991–1992 Medical Care Household Survey. Int J Obes Relat Metab Disord 2000; 24: 151–5PubMedCrossRef
53.
Smith R, Ronald J, Delaive K, et al. What are obstructive sleep apnea patients being treated for prior to this diagnosis? Chest 2002; 121: 164–72PubMedCrossRef
54.
Santamaria J, Iranzo A, Ma Mantserrat J, et al. Persistent sleepiness in CPAP treated obstructive sleep apnea patients: evaluation and treatment. Sleep Med Rev 2007; 11: 195–207PubMedCrossRef
55.
Tarasiuk A, Greenberg-Dotan S, Brin YS, et al. Determinants affecting health-care utilization in obstructive sleep apnea syndrome patients. Chest 2005; 128: 1310–4PubMedCrossRef
56.
Weaver TE, Grusteine RR. Adherence to continuous positive airway pressure therapy: the challenge to effective treatment. Proc Am Thorac Soc 2008; 15: 173–8CrossRef
57.
Simon-Tuval T, Reuveni H, Greenberg-Dontan S, et al. Low socioeconomic status is a risk factor for CPAP acceptance among adult OSAS patients requiring treatment. Sleep 2009; 32: 545–52PubMed
58.
Olsen S, Smith S, Oei T, et al. Health belief model predicts adherence to CPAP before experience with CPAP. Eur Respir J 2008; 32: 710–7PubMedCrossRef
59.
Reuveni H, Tarasiuk A, Wainstock T, et al. Awareness level of obstructive sleep apnea syndrome during routine unstructured interviews of a standardized patient by primary care physicians. Sleep 2004; 27: 1518–25PubMed
60.
Greenberg-Dotan S, Reuveni H, Simon-Tuval T, et al. Gender differences in morbidity and health care utilization among adult obstructive sleep apnea patients. Sleep 2007; 30: 1173–80PubMed
61.
Banno K, Manfreda J, Walld R, et al. Healthcare utilization in women with obstructive sleep apnea syndrome 2 years after diagnosis and treatment. Sleep 2006; 29: 1307–11PubMed
62.
Albarrak M, Banno K, Sabbagh AA, et al. Utilization of heathcare resources in obstructive sleep apnea syndrome: a 5-year follow-up study in men using CPAP. Sleep 2005; 28: 1306–11PubMed
63.
Banno K, Ramsey C, Walld R, et al. Expenditure on health care in obese women with and without sleep apnea. Sleep 2009; 32 (2): 247–52PubMed
64.
Pilcher JJ, Huffcutt AI. Effects of sleep deprivation on performance: a meta-analysis. Sleep 1996; 19: 318–26PubMed
65.
Berger LK, Cade BE, Ayas NT, et al. Extended work shifts and the risk of motor vehicle crashes among interns. N Engl J Med 2005; 352: 125–34CrossRef
66.
Boggild H, Knutsson A. Shift work, risk factors and cardiovascular disease. Scand J Work Environ Health 1999; 25: 85–99PubMedCrossRef
67.
Knutsson A. Health disorders of shift workers. Occup Med (Lond) 2003; 53 (2): 103–8CrossRef
68.
Schwartz JRL, Roth T. Shift work sleep disorder: burden of illness and approaches to management. Drugs 2006; 66 (18): 2357–70PubMedCrossRef
69.
Folkard S, Tucker P. Shift work, safety and productivity. Occup Med 2003; 53: 95–101CrossRef
70.
Drake CL, Roehrs T, Richardson G, et al. Shift work sleep disorder: prevalence and consequences beyond that of symptomatic day workers. Sleep 2004; 27: 1453–62PubMed
71.
Puca FM, Perrucci S, Prudenzano MP, et al. Quality of life in shift work syndrome. Funct Neurol 1996; 5: 261–8
72.
Dorrian J, Hussey F, Dawson D. Train driving efficiency and safety: examining the cost of fatigue. J Sleep Res 2007; 15: 1–11CrossRef
73.
Smith JE, Tolson JM. Recognition, diagnosis, and treatment of restless legs syndrome. J Am Acad Nurse Pract 2008; 20: 396–401PubMedCrossRef
74.
Garcia-Borreguero D, Egatz R, WInkelmann J, et al. Epidemiology of restless legs syndrome: the current status. Sleep Med Rev 2066; 10: 153–67CrossRef
75.
Allen RP, Wahers A, Montplaisir J, et al. Restless legs syndrome prevelence and impact: REST general population study. Arch Intern Med 2005; 165: 1286–95PubMedCrossRef
76.
Berger K, Luedemann J, Trenkwalder C, et al. Sex and the risk of restless legs syndrome in the general population. Arch Intern Med 2004; 164: 196–202PubMedCrossRef
77.
Phillips B, Young T, Finn L, et al. Epidemiology of restless legs symptoms in adults. Arch Intern Med 2000; 160 (14): 2137–41PubMedCrossRef
78.
Spiegelhalder K, Hornyak M. Restless legs syndrome in older adults. Cliin Geriatr Med 2008; 24: 167–80CrossRef
79.
Gomez-Esteban JC, Zarrantz JJ, Tijero R, et al. Restless legs syndrome in Parkinson’s disease. Mov Disord 2007; 22: 1912–6PubMedCrossRef
80.
Suzuki K, Ohida T, Sone T, et al. The prevalence of restless legs syndrome among pregnant women in Japan and the relationship between restless legs syndrome and sleep problems. Sleep 2003; 26: 672–7
81.
Kavanagh D, Siddiqui S, Geddes CC. Restless legs syndrome in patients on dialysis. Am J Kidney Dis 2005; 43: 763–71CrossRef
82.
Chasens ER. Understanding sleep in persons with diabetes. Diabetes Educ 2007; 33 (3): 435–6, 438, 441PubMedCrossRef
83.
Merlino G, Fraticci L, Valente M, et al. Association of restless legs syndrome in type 2 diabetes: case-control study. Sleep 2007; 14: 534–9
84.
Abetz L, Allen R, Follet A, et al. Evaluating the quality of life of patients with restless legs syndrome. Clin Ther 2004; 26 (6): 925–35PubMedCrossRef
85.
Kushiba C, Blaisdell B, Ferini-Strambi L. Burden of restless legs syndrome on health related quality of life. Qual Life Res 2007; 16: 617–24CrossRef
86.
Reinhold T, MÜller-Riemenschneider F, Willich SN, et al. Economic and human costs of restless legs syndrome. Pharmacoeconomics 2009; 27 (4): 267–79PubMedCrossRef
Metadata
Title
Economic Implications of Sleep Disorders
Authors
Dr Tracy L. Skaer
David A. Sclar
Publication date
01-11-2010
Publisher
Springer International Publishing
Published in
PharmacoEconomics / Issue 11/2010
Print ISSN: 1170-7690
Electronic ISSN: 1179-2027
DOI
https://doi.org/10.2165/11537390-000000000-00000

Other articles of this Issue 11/2010

PharmacoEconomics 11/2010 Go to the issue

Original Research Article

Economic Evaluation of Cinacalcet in the Treatment of Secondary Hyperparathyroidism in Italy

Short Communication

Methods of Model Calibration

Review Article

Cost Effectiveness of Pharmacogenomics

Editorial

New Prescription for the Spanish Drug Sector

Currene Opinion

Evaluation of Benefit-Risk

Original Research Article

Cost Effectiveness of Imiquimod 5% Cream Compared with Methyl Aminolevulinate-Based Photodynamic Therapy in the Treatment of Non-Hyperkeratotic, Non-Hypertrophic Actinic (Solar) Keratoses A Decision Tree Model